Viridian Therapeutics reported a Phase 3 win for elegrobart, an anti-IGF-1R antibody in thyroid eye disease, and said the program hit its primary endpoint in REVEAL-1. The study enrolled 132 patients and compared monthly and every-eight-week dosing against placebo, with the proptosis responder rate at week 24 used as the primary measure. Viridian said the monthly dosing regimen achieved a 54% responder rate versus 18% on placebo, and the every-eight-week cohort reached 63%. The company also reported higher complete resolution of diplopia in the monthly arm (51% vs 16% on placebo) along with a favorable mean proptosis change for monthly dosing, according to the company’s release. Amgen’s Tepezza already has market coverage for TED, and investors appear focused on whether elegrobart’s injection schedule and trial profile can translate into adoption despite cross-trial comparison hurdles.